NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
ID: 357492Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering the NCCIH Natural Product Early Phase Clinical Trial Award (R33), aimed at supporting investigator-initiated clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages applications for early phase trials that assess the impact of these products on specific biological targets and their potential clinical outcomes, with a focus on optimizing study designs and dosage. The initiative is crucial for advancing research in complementary and integrative health approaches, ensuring that projects adhere to rigorous scientific standards and include a Plan for Enhancing Diverse Perspectives (PEDP). The total estimated funding for this program is $1,050,000, with applications due by November 13, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAR-25-270.html.

    Point(s) of Contact
    Files
    Title
    Posted
    The National Institutes of Health (NIH) is issuing a funding opportunity through the NCCIH Natural Product Early Phase Clinical Trial Award (R33) to support investigator-initiated trials of natural products like botanicals and dietary supplements with strong scientific foundations. The R33 mechanism is designed for early phase clinical trials, focusing on replicating the impact of these natural products on specific biological targets and their potential clinical effects over a maximum of three years. The funding aims to assess various study designs, dosage optimization, and the combination of these products with other therapies. Projects must comply with rigorous methodological standards and demonstrate a clear rationale through preliminary data. A key requirement is the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity and collaboration in research efforts. The document outlines specific details about eligibility, application processes, and review criteria, while emphasizing the importance of rigorous scientific inquiry in advancing complementary and integrative health approaches.
    Similar Opportunities
    NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCCIH Natural Product Early Phase Clinical Trial Award (R33), aimed at funding early phase clinical trials focused on natural products such as botanicals and dietary supplements. This funding opportunity encourages research that rigorously evaluates the effects of these products on specific biological targets, with a total budget limit of $1,050,000 in direct costs available for up to three years of support. The initiative is particularly relevant for addressing health issues like chronic pain and gastrointestinal disorders, emphasizing the importance of diverse research collaborations and methodologies. Interested applicants must comply with NIH grants policies and submit their proposals by November 13, 2026, while also enhancing research diversity through a Plan for Enhancing Diverse Perspectives (PEDP). For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), has announced the NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33), aimed at supporting early-phase clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages applications that demonstrate a strong scientific basis for further testing, focusing on pharmacokinetics, bioavailability, and measurable effects on target mechanisms rather than just clinical symptoms. The award consists of two phases: the R61 phase provides up to three years of funding for milestone-driven studies, while the R33 phase may extend funding for an additional three years contingent upon achieving R61 milestones. Interested applicants can find more details and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with a total estimated program funding of $350,000 and a closing date for applications set for November 13, 2026.
    NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), invites applications for the NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33), aimed at supporting early-phase clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages research that evaluates the pharmacokinetics, safety, and efficacy of these natural products, with a focus on advancing promising interventions backed by prior scientific evidence. The program is designed to foster innovative clinical research that enhances understanding of the beneficial impacts of natural products on health conditions, while ensuring inclusivity through a Plan for Enhancing Diverse Perspectives (PEDP). Applicants may request up to $350,000 per year, with a project duration of up to six years contingent upon successful milestone completion, and the application deadline is November 13, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), is inviting applications for the "NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)" grant, aimed at advancing research on natural products such as botanicals and dietary supplements. This funding opportunity encourages mid-phase clinical trials that are hypothesis-driven, focusing on determining optimal dosing or identifying patient phenotypes for future efficacy studies, while explicitly excluding trials for cancer treatment. Eligible applicants include a diverse range of organizations, such as historically black colleges, tribal colleges, and community-based organizations, with a funding ceiling of $350,000 and a submission deadline of November 13, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-24-115.html.
    NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)" aimed at supporting mid-phase clinical trials of natural products, including botanicals, dietary supplements, and probiotics, that demonstrate promising preliminary evidence for health benefits. Applicants are required to provide sufficient preliminary data, adhere to FDA regulations, and develop a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity in research, with a focus on determining optimal dosing and patient responsiveness before advancing to larger efficacy trials. This funding opportunity is critical for addressing knowledge gaps in complementary health approaches, particularly in symptom management and health disparities. The estimated total program funding is $350,000, with applications due by November 13, 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment of a Clinical Coordinating Center (CCC) to support multi-site investigator-initiated clinical trials focused on natural products, such as botanicals and dietary supplements. Applicants are required to submit a comprehensive plan detailing project management, participant recruitment, and clinical trial execution, while also ensuring alignment with NIH standards. This initiative emphasizes the importance of evidence-based research in natural products and mandates the submission of a corresponding Data Coordinating Center (DCC) proposal to oversee data management and analysis. Interested applicants should note that the application deadline is July 15, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For additional details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-24-123.html.
    Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for cooperative agreements to establish a Clinical Coordinating Center (CCC) for multi-site, investigator-initiated clinical trials focused on the effects of natural products, such as botanicals and dietary supplements. Applicants are required to develop a comprehensive scientific and operational plan for the clinical trial, including project management, participant recruitment, and performance milestones, while also submitting a companion Data Coordinating Center (DCC) application. This initiative aims to generate robust clinical data to inform integrative health approaches and public health strategies, with applications opening on January 20, 2025, and closing on July 14, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-312.html.
    Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Natural Product Multi-Site Clinical Trial Data Coordinating Center (DCC) through a cooperative agreement mechanism. This initiative invites applications for a DCC that will collaborate with a Clinical Coordinating Center (CCC) to conduct multi-site clinical trials focused on the efficacy and effectiveness of natural products, requiring simultaneous submission of both applications. The program emphasizes the importance of maintaining data integrity, promoting diversity in participant recruitment, and achieving specific milestones for continued funding, while also necessitating a Plan for Enhancing Diverse Perspectives (PEDP) to ensure inclusivity in research. Interested applicants can find more information and application details on the NIH grants website, with a submission deadline of July 14, 2026, and a contact email for inquiries at grantsinfo@nih.gov.
    Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), is offering a funding opportunity for feasibility clinical trials focused on mind and body interventions addressing high-priority research topics. The objective is to support R34 planning grants that gather essential data necessary for the design and planning of future full-scale efficacy studies, specifically examining aspects such as intervention acceptability, recruitment strategies, and data collection procedures. This initiative is crucial for advancing research in nonpharmacological approaches to symptom management, particularly relevant in the context of increasing healthcare demands. Interested applicants can apply for grants of up to $450,000 over three years, with a submission deadline of November 13, 2026. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-084.html.
    NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), has announced a funding opportunity for multi-site feasibility clinical trials focused on mind and body interventions under the R01 grant mechanism. This initiative aims to support studies that gather essential data necessary for planning larger efficacy trials, with specific objectives including assessing recruitment feasibility, intervention fidelity, and participant adherence across multiple sites. The funding is crucial for advancing research in complementary and integrative health, addressing public health challenges, and fostering innovative healthcare approaches. Eligible applicants can request up to $350,000 in direct costs per year, with applications due by November 17, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-267.html.